Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Robert Ozols
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Physiology
Concepts & Ideas
Anatomy
Sign-in to see full Profile
Network (preview)
30
O'Dwyer, Peter
26
Hamilton, Thomas
13
Bookman, Michael
11
Hudes, Gary
11
Schilder, Russell
9
McAleer, Cecilia
8
Langer, Corey
6
McGuire, William
6
Litwin, Samuel
6
Boente, MP
6
Daly, Mary
5
Greer, Benjamin
4
Millenson, Michael
4
Gallo, James
4
Giantonio, Bruce
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Robert Ozols (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Morgan Robert J; Alvarez Ronald D; Armstrong Deborah K; Boston Barry; Chen Lee-may; Copeland Larry; Fowler Jeff; Gaffney David K; Gershenson David; Greer Benjamin E; Grigsby Perry W; Havrilesky Laura J; Johnston Carolyn; Lancaster Johnathan M; Lele Shashikant; Matulonis Ursula; O'Malley David; Ozols Robert F; Remmenga Steven W; Sabbatini Paul; Schink Julian; Teng Nelson;
Ovarian cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(8):766-94.
-
2008: Ozols Robert F
Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer.
Advances in experimental medicine and biology 2008;622():131-43.
-
2007: Bast Robert C; Thigpen J Tate; Arbuck Susan G; Basen-Engquist Karen; Burke Laurie B; Freedman Ralph; Horning Sandra J; Ozols Robert; Rustin Gordon J; Spriggs David; Wenzel Lari B; Pazdur Richard
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Gynecologic oncology 2007;107(2):173-6.
-
2007: Hess L M; Barakat R; Tian C; Ozols R F; Alberts D S
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;107(2):260-5.
-
2007: Winter William E; Maxwell G Larry; Tian Chunqiao; Carlson Jay W; Ozols Robert F; Rose Peter G; Markman Maurie; Armstrong Deborah K; Muggia Franco; McGuire William P;
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3621-7.
-
2007: Mabuchi Seiji; Altomare Deborah A; Cheung Mitchell; Zhang Lili; Poulikakos Poulikos I; Hensley Harvey H; Schilder Russell J; Ozols Robert F; Testa Joseph R
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4261-70.
-
2007: Bast Robert C; Brewer Molly; Zou Changping; Hernandez Mary A; Daley Mary; Ozols Robert; Lu Karen; Lu Zhen; Badgwell Donna; Mills Gordon B; Skates Steven; Zhang Zhen; Chan Dan; Lokshin Anna; Yu Yinhua
Prevention and early detection of ovarian cancer: mission impossible?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;174():91-100.
-
2006: Alberts D S; Markman M; Muggia F; Ozols R F; Eldermire E; Bookman M A; Chen T; Curtin J; Hess L M; Liebes L; Young R C; Trimble E
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
Gynecologic oncology 2006;103(3):783-92.
-
2006: Cai Kathy Qi; Klein-Szanto Andres; Karthik Devarajan; Edelson Mitchell; Daly Mary B; Ozols Robert F; Lynch Henry T; Godwin Andrew K; Xu Xiang-Xi
Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.
Gynecologic oncology 2006;103(2):719-28.
-
2006: Morgan Robert J; Alvarez Ronald D; Armstrong Deborah K; Chen Lee-May; Copeland Larry; Fowler Jeff; Gaffney David K; Gershenson David; Greer Benjamin E; Johnston Carolyn; Lancaster Johnathan M; Lele Shashikant; Matulonis Ursula; Ozols Robert F; Remmenga Steven W; Sabbatini Paul; Soper John; Teng Nelson;
Ovarian cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(9):912-39.
-
2006: Ozols Robert F; Bookman Michael A; du Bois Andreas; Pfisterer Jacobus; Reuss Alexander; Young Robert C
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Gynecologic oncology 2006;103(1):1-6.
-
2006: Ozols R F
Challenges for chemotherapy in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v181-7.
-
2006: Ozols Robert F
Systemic therapy for ovarian cancer: current status and new treatments.
Seminars in oncology 2006;33(2 Suppl 6):S3-11.
-
2006: Ozols Robert F; Bookman Michael A; Young Robert C
Intraperitoneal chemotherapy for ovarian cancer.
The New England journal of medicine 2006;354(15):1641-3; author reply 1641-3.
-
2005: Greer Benjamin E; Bundy Brian N; Ozols Robert F; Fowler Jeffrey M; Clarke-Pearson Daniel; Burger Robert A; Mannel Robert; DeGeest Koen; Hartenbach Ellen M; Baergen Rebecca N; Copeland Larry J
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;99(1):71-9.
-
2005: Ozols Robert F
Gemcitabine and carboplatin in second-line ovarian cancer.
Seminars in oncology 2005;32(4 Suppl 6):S4-8.
-
2005: Ozols R F
Treatment goals in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15 Suppl 1():3-11.
-
2005: Vermorken J B; Parmar M K B; Brady M F; Eisenhauer E A; Hogberg T; Ozols R F; Rochon J; Rustin G J S; Sagae S; Verheijen R H M;
Clinical trials in ovarian carcinoma: study methodology.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii20-viii29.
-
2004: Ozols Robert F
Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(6):555-60.
-
2004: Ozols Robert F
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 2():S60-73.
-
2004: Daly Mary B; Ozols Robert F
Symptoms of ovarian cancer--where to set the bar?
JAMA : the journal of the American Medical Association 2004;291(22):2755-6.
-
2004: Ozols Robert F; Bookman Michael A; Connolly Denise C; Daly Mary B; Godwin Andrew K; Schilder Russell J; Xu Xiangxi; Hamilton Thomas C
Focus on epithelial ovarian cancer.
Cancer cell 2004;5(1):19-24.
-
2004: Ozols Robert F
Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
Cancer investigation 2004;22 Suppl 2():11-20.
-
2003: Roland Isabelle H; Yang Wan-Lin; Yang Dong-Hua; Daly Mary B; Ozols Robert F; Hamilton Thomas C; Lynch Henry T; Godwin Andrew K; Xu Xiang-Xi
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.
Cancer 2003;98(12):2607-23.
-
2003: Bookman M A; Greer B E; Ozols R F
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):735-40.
-
2003: Bookman M A; Greer B E; Ozols R F
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():149-55.
-
2003: Ozols Robert F; Bundy Brian N; Greer Benjamin E; Fowler Jeffrey M; Clarke-Pearson Daniel; Burger Robert A; Mannel Robert S; DeGeest Koen; Hartenbach Ellen M; Baergen Rebecca;
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3194-200.
-
2003: Ozols Robert F; Daly Mary B; Klein-Szanto Andres; Hamilton Thomas C; Bast Robert C; Brewer Molly A
Specific keynote: chemoprevention of ovarian cancer: the journey begins.
Gynecologic oncology 2003;88(1 Pt 2):S59-66; discussion S67-70.
-
2002: Ozols Robert F; Markman Maurie; Thigpen J Tate
ICON3 and chemotherapy for ovarian cancer.
Lancet 2002;360(9350):2086-7; author reply 2088.
-
2002: Ozols Robert F
Update on the management of ovarian cancer.
Cancer journal (Sudbury, Mass.) 2002;8 Suppl 1():S22-30.
-
2002: Daly Mary B; Ozols Robert F
The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics.
Cancer cell 2002;1(2):111-2.
-
2002: Ozols Robert F
Future directions in the treatment of ovarian cancer.
Seminars in oncology 2002;29(1 Suppl 1):32-42.
-
2001: Ozols R F
The current role of gemcitabine in ovarian cancer.
Seminars in oncology 2001;28(2 Suppl 7):18-24.
-
2001: Schilder R J; Gallo J M; Millenson M M; Bookman M A; Weiner L M; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams A L; Ciccotto S; Ozols R F
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1183-94.
-
2000: Berek J S; Bertelsen K; du Bois A; Brady M F; Carmichael J; Eisenhauer E A; Gore M; Grenman S; Hamilton T C; Hansen S W; Harper P G; Horvath G; Kaye S B; Lück H J; Lund B; McGuire W P; Neijt J P; Ozols R F; Parmar M K; Piccart-Gebhart M J; van Rijswijk R; Rosenberg P; Rustin G J; Sessa C; Thigpen J T; Tropé C; Tuxen M K; Vergote I; Vermorken J B; Willemse P H
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]
Gynécologie, obstétrique & fertilité 2000;28(7-8):576-83.
-
2000: Ozols R F
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
Seminars in oncology 2000;27(3 Suppl 7):47-9.
-
2000: Ozols R F
Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Seminars in oncology 2000;27(3 Suppl 7):3-7.
-
2000: Ozols R F
The role of gemcitabine in the treatment of ovarian cancer.
Seminars in oncology 2000;27(1 Suppl 2):40-7.
-
2000: Langer C J; McAleer C A; Bonjo C A; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols R F
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
European journal of cancer (Oxford, England : 1990) 2000;36(2):183-93.
-
1999: Ozols R F
Chemotherapy for ovarian cancer.
Seminars in oncology 1999;26(6 Suppl 18):34-40.
-
1999: Ozols R F
Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin.
The cancer journal from Scientific American 1999;5(6):336-8.
-
1999: Schilder R J; Johnson S; Gallo J; Kindsfather S; Rogers B; Bookman M A; Millenson M M; Boente M; Rosenblum N; Litwin S; Ozols R F
Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2198-207.
-
1999: Langer C J; Gandara D R; Calvert P; Edelman M J; Ozols R F
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Seminars in oncology 1999;26(1 Suppl 4):12-8.
-
1999: Ozols R F
Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Seminars in oncology 1999;26(1 Suppl 2):84-9.
-
1999: Berek J S; Bertelsen K; du Bois A; Brady M F; Carmichael J; Eisenhauer E A; Gore M; Grenman S; Hamilton T C; Hansen S W; Harper P G; Horvath G; Kaye S B; Lück H J; Lund B; McGuire W P; Neijt J P; Ozols R F; Parmar M K; Piccart-Gebhart M J; van Rijswijk R; Rosenberg P; Rustin G J; Sessa C; Willemse P H
Advanced epithelial ovarian cancer: 1998 consensus statements.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():87-92.
-
1999: Ozols R F; Gore M; Tropé C; Grenman S
Intraperitoneal treatment and dose-intense therapy in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():59-64.
-
1999: McGuire W P; Brady M F; Ozols R F
The Gynecologic Oncology Group experience in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():29-34.
-
1998: Langer C J; Calvert P; Ozols R F
Gemcitabine and carboplatin in combination: phase I and phase II studies.
Seminars in oncology 1998;25(4 Suppl 9):51-4.
-
1998: McGuire W P; Ozols R F
Chemotherapy of advanced ovarian cancer.
Seminars in oncology 1998;25(3):340-8.
-
1998: Ozols R F
Chemotherapy of ovarian cancer.
Cancer treatment and research 1998;95():219-34.
-
1997: Bookman M A; Kloth D D; Kover P E; Smolinski S; Ozols R F
Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Seminars in oncology 1997;24(6 Suppl 19):S19-13-S19-15.
-
1997: Ozols R F
Update of the NCCN ovarian cancer practice guidelines.
Oncology (Williston Park, N.Y.) 1997;11(11A):95-105.
-
1997: Ozols R F
Future directions in the chemotherapy of ovarian cancer.
Seminars in oncology 1997;24(5 Suppl 15):S15-86-S15-90.
-
1997: Langer C J; Millenson M; Rosvold E; Litwin S; McAleer C A; Bonjo C A; Ozols R
Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Seminars in oncology 1997;24(4 Suppl 12):S12-81-S12-88.
-
1997: Bookman M A; Kloth D D; Kover P E; Smolinski S; Ozols R F
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):611-4.
-
1997: Ozols R F
Gynecologic oncology group trials in ovarian carcinoma.
Seminars in oncology 1997;24(1 Suppl 2):S2-10-S2-12.
-
1997: Ozols R F; Vermorken J B
Chemotherapy of advanced ovarian cancer: current status and future directions.
Seminars in oncology 1997;24(1 Suppl 2):S2-1-S2-9.
-
1997: O'Reilly S; Fleming G F; Barker S D; Walczak J R; Bookman M A; McGuire W P; Schilder R J; Alvarez R D; Armstrong D K; Horowitz I R; Ozols R F; Rowinsky E K
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):177-86.
-
1996: Langer C J; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer C A; Bonjo C A; Ozols R
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Seminars in oncology 1996;23(6 Suppl 16):35-41.
-
1996: Bookman M A; McGuire W P; Kilpatrick D; Keenan E; Hogan W M; Johnson S W; O'Dwyer P; Rowinsky E; Gallion H H; Ozols R F
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1895-902.
-
1996: Obasaju C K; Johnson S W; Rogatko A; Kilpatrick D; Brennan J M; Hamilton T C; Ozols R F; O'Dwyer P J; Gallo J M
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):549-52.
-
1996: O'Dwyer P J; Hamilton T C; LaCreta F P; Gallo J M; Kilpatrick D; Halbherr T; Brennan J; Bookman M A; Hoffman J; Young R C; Comis R L; Ozols R F
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):249-56.
-
1996: Boente M P; Yeh K; Hogan W M; Ozols R F
Current status of staging laparotomy in colorectal and ovarian cancer.
Cancer treatment and research 1996;82():337-57.
-
1996: Leighton J; Clark J; Giantonio B; Ozols R; Hudes G
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1996;16():524-63.
-
1996: Schröder C P; Godwin A K; O'Dwyer P J; Tew K D; Hamilton T C; Ozols R F
Glutathione and drug resistance.
Cancer investigation 1996;14(2):158-68.
-
1996: Hageboutros A; Hudes G R; Brennan J; Green F; Hoffman J; LaCreta F P; Colofiore J; Martin D S; Ozols R F; O'Dwyer P J
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Cancer chemotherapy and pharmacology 1996;37(3):229-34.
-
1995: Ozols R F
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Seminars in oncology 1995;22(6 Suppl 15):1-6.
-
1995: Ozols R F
Outcome issues in ovarian cancer.
Oncology (Williston Park, N.Y.) 1995;9(11 Suppl):135-9.
-
1995: Yao K S; Godwin A K; Johnson S W; Ozols R F; O'Dwyer P J; Hamilton T C
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
Cancer research 1995;55(19):4367-74.
-
1995: Gallo J M; Brennan J; Hamilton T C; Halbherr T; Laub P B; Ozols R F; O'Dwyer P J
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Cancer research 1995;55(20):4507-11.
-
1995: Ozols R F
Current status of chemotherapy for ovarian cancer.
Seminars in oncology 1995;22(5 Suppl 12):61-6.
-
1995: Langer C J; Leighton J C; Comis R L; O'Dwyer P J; McAleer C A; Bonjo C A; Engstrom P F; Litwin S; Johnson S; Ozols R F
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Seminars in oncology 1995;22(4 Suppl 9):18-29.
-
1995: Langer C J; Leighton J C; Comis R L; O'Dwyer P J; McAleer C A; Bonjo C A; Engstrom P F; Litwin S; Ozols R F
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1860-70.
-
1995: Ozols R F
Carboplatin and paclitaxel in ovarian cancer.
Seminars in oncology 1995;22(3 Suppl 6):78-83.
-
1995: Langer C J; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Seminars in oncology 1995;22(3 Suppl 6):64-9.
-
1995: Schultz D C; Vanderveer L; Buetow K H; Boente M P; Ozols R F; Hamilton T C; Godwin A K
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Cancer research 1995;55(10):2150-7.
-
1995: O'Dwyer P J; Hamilton T C; Yao K S; Tew K D; Ozols R F
Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.
Hematology/oncology clinics of North America 1995;9(2):383-96.
-
1995: Schilder R J; Boente M P; Corn B W; Lanciano R M; Young R C; Ozols R F
The management of early ovarian cancer.
Oncology (Williston Park, N.Y.) 1995;9(2):171-82; discussion 185-7.
-
1995: Hudes G R; Kosierowski R; Greenberg R; Ramsey H E; Fox S C; Ozols R F; McAleer C A; Giantonio B J
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Investigational new drugs 1995;13(3):235-40.
-
1995: Haas N B; Schilder R J; Nash S; Weiner L M; Catalano R C; Ozols R F; O'Dwyer P J
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Investigational new drugs 1995;13(3):229-33.
-
1995: Hageboutros A; Rogatko A; Newman E M; McAleer C; Brennan J; LaCreta F P; Hudes G R; Ozols R F; O'Dwyer P J
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Cancer chemotherapy and pharmacology 1995;35(3):205-12.
-
1994: Ozols R F
Research directions in epithelial ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S168-73.
-
1994: Corn B W; Lanciano R M; Boente M; Hunter W M; Ladazack J; Ozols R F
Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
Cancer 1994;74(11):2979-83.
-
1994: Johnson S W; Swiggard P A; Handel L M; Brennan J M; Godwin A K; Ozols R F; Hamilton T C
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Cancer research 1994;54(22):5911-6.
-
1994: Lacreta F P; Brennan J M; Hamilton T C; Ozols R F; O'Dwyer P J
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(6):835-42.
-
1994: Ozols R F
Treatment of ovarian cancer: current status.
Seminars in oncology 1994;21(2 Suppl 2):1-9; quiz 10, 58.
-
1994: Haas N B; LaCreta F P; Walczak J; Hudes G R; Brennan J M; Ozols R F; O'Dwyer P J
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Cancer research 1994;54(5):1220-6.
-
1994: Johnson S W; Perez R P; Godwin A K; Yeung A T; Handel L M; Ozols R F; Hamilton T C
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
Biochemical pharmacology 1994;47(4):689-97.
-
1994: Ozols R F
Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S39-43.
-
1994: Hudes G R; Ozols R F; Giantonio B
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1994;15():531-54.
-
1993: Hamilton T C; O'Dwyer P J; Ozols R F
Platinum analogues in preclinical and clinical development.
Current opinion in oncology 1993;5(6):1010-6.
-
1993: Hamaguchi K; Godwin A K; Yakushiji M; O'Dwyer P J; Ozols R F; Hamilton T C
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Cancer research 1993;53(21):5225-32.
-
1993: Ozols R F
[Epithelial cancer of the ovary: current data]
Bulletin du cancer 1993;80(11):955-70.
-
1993: Ozols R F; O'Dwyer P J; Hamilton T C
Clinical reversal of drug resistance in ovarian cancer.
Gynecologic oncology 1993;51(1):90-6.
-
1993: Brennan J M; O'Dwyer P J; Ozols R F; LaCreta F P
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.
Journal of chromatography 1993;620(1):121-8.
-
1993: Yao K; Godwin A K; Ozols R F; Hamilton T C; O'Dwyer P J
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Cancer research 1993;53(16):3662-6.
-
1993: Haas N B; Hines J B; Hudes G R; Johnston N; Ozols R F; O'Dwyer P J
Phase I trial of 5-fluorouracil by 24-hour infusion weekly.
Investigational new drugs 1993;11(2-3):181-5.
-
1993: Perez R P; Hamilton T C; Ozols R F; Young R C
Mechanisms and modulation of resistance to chemotherapy in ovarian cancer.
Cancer 1993;71(4 Suppl):1571-80.
-
1993: Johnson S W; Ozols R F; Hamilton T C
Mechanisms of drug resistance in ovarian cancer.
Cancer 1993;71(2 Suppl):644-9.
-
1993: Ozols R F; Thigpen J T; Dauplat J; Colombo N; Piccart M J; Bertelsen K; Levin L; Lund B
Advanced ovarian cancer. Dose intensity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():49-56.
-
1993: Giantonio B; Ozols R F; Hudes G R
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1993;14():498-529.
-
1992: O'Dwyer P J; LaCreta F P; Schilder R; Nash S; McAleer C; Miller L L; Hudes G R; Ozols R F
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1352-8.
-
1992: Ozols R F
Chemotherapy for advanced epithelial ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):879-94.
-
1992: Perez R P; Nash S L; Ozols R F; Comis R L; O'Dwyer P J
Phase II study of amonafide in advanced and recurrent sarcoma patients.
Investigational new drugs 1992;10(2):99-101.
-
1992: O'Dwyer P J; Hamilton T C; Young R C; LaCreta F P; Carp N; Tew K D; Padavic K; Comis R L; Ozols R F
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
Journal of the National Cancer Institute 1992;84(4):264-7.
-
1992: Ozols R F
New developments with carboplatin in the treatment of ovarian cancer.
Seminars in oncology 1992;19(1 Suppl 2):85-9.
-
1992: Ozols R F
Advances in the chemotherapy of gynecologic malignancies.
Hematological oncology 1992;10(1):43-51.
-
1992: Rosvold E; Schilder R; Walczak J; DiFino S M; Flynn P J; Banerjee T K; Heim W J; Engstrom P F; Ozols R F; O'Dwyer P J
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 1992;29(4):305-8.
-
1992: Ozols R F
Role of carboplatin in ovarian cancer. Current results and thoughts for the future.
Acta obstetricia et gynecologica Scandinavica. Supplement 1992;155():75-7.
-
1992: Ozols R F
Role of chemotherapy in the future treatment of ovarian cancer.
Acta obstetricia et gynecologica Scandinavica. Supplement 1992;155():55-60.
-
1992: Schilder R J; Ozols R F
New therapies for ovarian cancer.
Cancer investigation 1992;10(4):307-15.
-
1991: O'Dwyer P J; Hudes G R; Colofiore J; Walczak J; Hoffman J; LaCreta F P; Comis R L; Martin D S; Ozols R F
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Journal of the National Cancer Institute 1991;83(17):1235-40.
-
1991: Ozols R F; Young R C
Ovarian cancer: where to next?
Seminars in oncology 1991;18(3):307-10.
-
1991: Ozols R F; Young R C
Chemotherapy of ovarian cancer.
Seminars in oncology 1991;18(3):222-32.
-
1991: Perez R P; Godwin A K; Hamilton T C; Ozols R F
Ovarian cancer biology.
Seminars in oncology 1991;18(3):186-204.
-
1991: Perez R P; O'Dwyer P J; Handel L M; Ozols R F; Hamilton T C
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
International journal of cancer. Journal international du cancer 1991;48(2):265-9.
-
1991: Ozols R F
Ovarian cancer: new clinical approaches.
Cancer treatment reviews 1991;18 Suppl A():77-83.
-
1991: O'Dwyer P J; Paul A R; Hudes G R; Walczak J; Ozols R F; Comis R L
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
Investigational new drugs 1991;9(1):65-7.
-
1990: Ozols R F; O'Dwyer P J; Hamilton T C; Young R C
The role of glutathione in drug resistance.
Cancer treatment reviews 1990;17 Suppl A():45-50.
-
1990: Schilder R J; Hall L; Monks A; Handel L M; Fornace A J; Ozols R F; Fojo A T; Hamilton T C
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.
International journal of cancer. Journal international du cancer 1990;45(3):416-22.
-
1990: Hamilton T C; Ozols R F; Dabrow M B
Multidrug resistance to alkylating agents and platinum compounds: state of our knowledge.
Oncology (Williston Park, N.Y.) 1990;4(3):101-6; discussion 106, 109.
-
1990: Perez R P; Hamilton T C; Ozols R F
Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.
Pharmacology & therapeutics 1990;48(1):19-27.
-
1989: Ozols R F
Cisplatin dose intensity.
Seminars in oncology 1989;16(4 Suppl 6):22-30.
-
1989: Ozols R F
Optimal dosing with carboplatin.
Seminars in oncology 1989;16(2 Suppl 5):14-8.
Sign-in to see more
